Existing 40 MW Operating Data Center Provides Current Revenue Base as Company Advances Growth PlanCollaboration with Super Micro and PDM along ...

Hyderabad's biggest strength remains their batting order. The opening pair of Travis Head and Abhishek Sharma remains the ...

Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow ...

Orphan designation reflects unmet need in RP rather than evidence of efficacy, while offering development incentives and potential post-approval market exclusivity for qualifying rare diseases.

Transaction expected to mark Actelis’ entry into the high-growth AI-driven data center networking market, leveraging Exaware’s rapidly expanding footprint across data center environments Acquisition ...

Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT), through its operating subsidiary Duos Edge AI, Inc., ...

EquityInsider.com Sector Commentary — A pivotal shift is already taking place in the global commodities market right now. Bloomberg's latest review of sovereign-led price floors shows a major ...

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patient ...

Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration The 12-16-week open-label study evaluated Ruxoprubart as ...

T Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower functional decline, reduced risk of ALS-related ...

Construction commences on portfolio that will add strong recurring revenue stream VANCOUVER, BRITISH COLUMBIA / ACCESS ...